Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial

EuroIntervention. 2008 Aug;4(2):234-41. doi: 10.4244/eijv4i2a42.

Abstract

Aims: The aim of this study was to evaluate the effectiveness of titanium-nitride-oxide (TITANOX)-coated stent and paclitaxel-eluting stent (PES) in patients presenting with acute myocardial infarction (MI).

Methods and results: A total of 425 patients presenting with acute non-ST-elevation MI or ST-elevation MI were randomly assigned to receive TITANOX-coated stent or PES. The primary end point was a composite of MI, target lesion revascularisation (TLR) or death from cardiac causes. At 12 months, there was no significant difference between patients receiving TITANOX-coated stent or PES in the rates of primary end point (10.3% vs. 12.8%, P=0.5), MI (4.2% vs. 8.1%, P=0.1), or TLR (9.3% vs. 7.1%, P=0.5), respectively. The incidence of stent thrombosis, defined according to Academic Research Consortium classification, was significantly lower in the TITANOX group compared to the PES group (0.9% vs. 4.3%, P=0.03).

Conclusions: TITANOX-coated stent and PES resulted in comparable clinical outcomes during 12 months follow-up among patients treated for acute MI.

Trial registration: ClinicalTrials.gov NCT00495664.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary*
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Disease-Free Survival
  • Drug-Eluting Stents*
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Myocardial Infarction / epidemiology
  • Myocardial Infarction / therapy*
  • Paclitaxel / administration & dosage*
  • Recurrence
  • Risk Factors
  • Thrombosis / prevention & control
  • Titanium*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Phytogenic
  • titanium-nitride-oxide
  • Titanium
  • Paclitaxel

Associated data

  • ClinicalTrials.gov/NCT00495664